{
    "nctId": "NCT00718952",
    "officialTitle": "Multi-centre, Prospective, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Treatment of Pulmonary Arterial Hypertension With Vardenafil in China",
    "inclusionCriteria": "* Subjects aged 12-65.\n* Confirmed idiopathic pulmonary hypertension, connective tissue disease associated pulmonary hypertension, congenital heart disease(with Eisenmenger syndrome) associated pulmonary hypertension.\n* Baseline 6-minutes walking distance 150m-550m.\n* WHO pulmonary hypertension function II-III with non-responder to calcium channel blockers.\n* Documented written informed consent.\n* Must have minimum age of 12 Years\n* Must have maximum age of 65 Years",
    "exclusionCriteria": "* The other types of pulmonary hypertension.\n* Subjects who refuse to subscribe written informed consents or can't cooperate with the trial well.\n* Subjects with serious acute or chronic disease involved liver, kidney, and brain or have to use potent CYP3A4-inhibitor or nitrate to treat the underlying diseases.\n* Subjects who are currently treated with sildenafil for PAH or taking sildenafil or tadalafil.\n* Other contraindications in package insert."
}